Beam Therapeutics Inc (NAS:BEAM)
$ 21.26 -1.28 (-5.68%) Market Cap: 1.75 Bil Enterprise Value: 928.86 Mil PE Ratio: 0 PB Ratio: 2.03 GF Score: 39/100

Beam Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 03, 2023 / 02:10PM GMT
Release Date Price: $30.13 (-1.60%)
Debjit Chattopadhyay
Guggenheim - MD, Biotechnology

Good morning, and thank you for joining the fifth annual Guggenheim Genomic Medicines and Rare Disease Conference. I am Debjit and my pleasure to have John Evans, the Chief Executive Officer of Beam Therapeutics.

John Evans
Beam Therapeutics Inc. - CEO & Board Member

Great to be here.

Questions & Answers

Debjit Chattopadhyay
Guggenheim - MD, Biotechnology

Awesome, so let's maybe help people understand base editing and more because I think a lot of people don't understand what Beam stands for.

John Evans
Beam Therapeutics Inc. - CEO & Board Member

That's right. Yeah, it's actually a joke we tell that Beam stands for base editing and more, and we're always looking for what the And more is. And I think we've figured a lot of things out actually that fit into that bucket.

So Beam is a next-generation gene editing company. We work on CRISPR, but it's a new form of CRISPR. So we're using CRISPR

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot